Related Experiment Video
Updated: Mar 16, 2026

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
Published on: May 13, 2021
Oncolytic virotherapy using herpes simplex virus: how far have we come?
Nicolas As Sokolowski1, Helen Rizos2, Russell J Diefenbach1
1Centre for Virus Research, Westmead Millennium Institute for Medical Research, The University of Sydney, NSW, Australia.
Abstract:
Oncolytic virotherapy exploits the properties of human viruses to naturally cytolysis of cancer cells. The human pathogen herpes simplex virus (HSV) has proven particularly amenable for use in oncolytic virotherapy. The relative safety of HSV coupled with extensive knowledge on how HSV interacts with the host has provided a platform for manipulating HSV to enhance the targeting and killing of human cancer cells. This has culminated in the approval of talimogene laherparepvec for the treatment of melanoma. This review focuses on the development of HSV as an oncolytic virus and where the field is likely to head in the future.
Related Concept Videos
Tumor Immunotherapy
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Subviral Agents
Mechanisms of Retrovirus-induced Cancers

